Hypertension related to the antitumor treatment with angiogenesis inhibitors: An iatrogenic hypertension [Артериальная гипертония как кардиотоксическая реакция на противоопухолевую терапию: что мы знаем о новом виде ятрогенной гипертонии]

One of the key regulators of vascular tone is the vascular endothelial growh factor (VEGF), which can enhance the production of nitric oxide, a potent vasodilator, and reduce vascular resistance by generating new vessels. Both mechanisms contribute to blood pressure decrease. The implementation of a new class of antitumor therapy-inhibitors of VEGF signaling pathway-results in the growh of cardiovascular complications such as arterial hypertension (HTN). The paper analyzes the causes of HTN development, approaches to the timely diagnosis of HTN and the correct assessment of cardiovascular risk before administration of VEGF inhibitors and during the treatment. We also review the features of the approaches of elevated blood pressure management in patients receiving targeted therapy. © 2018 All-Russian Public Organization Antihypertensive League. All Rights Reserved.

Авторы
Издательство
All-Russian Public Organization Antihypertensive League
Номер выпуска
4
Язык
Русский
Страницы
384-395
Статус
Опубликовано
Том
24
Год
2018
Организации
  • 1 Peoples' Friendship University of Russia, 6 Miklukho-Maklay street, Moscow, 117198, Russian Federation
Ключевые слова
Cardio-oncology; Hypertension; Tyrosine kinase inhibitors
Дата создания
04.02.2019
Дата изменения
08.02.2022
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/36373/
Поделиться

Другие записи